We are live on
!
Find out more
PCH
Polar Capital Holdings Portfolio holdings
AUM
$42.4B
1-Year Est. Return
181.11%
This Fund
S&P 500
This Quarter
Est. Return
-16.7%
1 Year Est. Return
+181.11%
3 Year Est. Return
+584.8%
5 Year Est. Return
+777.19%
10 Year Est. Return
–
AUM
$17B
AUM Growth
-$5.13B
(-23%)
Cap. Flow
-$794M
Cap. Flow
% of AUM
-4.67%
Top 10 Holdings %
Top 10 Hldgs %
43.02%
Holding
494
New
36
Increased
156
Reduced
156
Closed
61
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Salesforce
CRM
|
+$108M |
| 2 |
Visa
V
|
+$102M |
| 3 |
Mercado Libre
MELI
|
+$73M |
| 4 |
Enphase Energy
ENPH
|
+$58.6M |
| 5 |
Snowflake
SNOW
|
+$57.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
+$147M |
| 2 |
Y
Alleghany Corp
Y
|
+$137M |
| 3 |
Applied Materials
AMAT
|
+$116M |
| 4 |
Alphabet (Google) Class C
GOOG
|
+$115M |
| 5 |
Alphabet (Google) Class A
GOOGL
|
+$111M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 30.66% |
| 2 | Industrials | 25.1% |
| 3 | Healthcare | 17.44% |
| 4 | Financials | 14.96% |
| 5 | Communication Services | 5.35% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
151
Humana
HUM
$48.3B
| $17.3M | 0.1% |
+37,000
| New | +$16.5M |
|
152
MKS Inc
MKSI
$16.1B
| $17.1M | 0.1% |
166,250
| – | – |
|
|
AKYA
153
DELISTED
Akoya BioSciences
AKYA
| $16.9M | 0.1% |
1,315,470
| – | – |
|
154
Wells Fargo
WFC
$276B
| $16.8M | 0.1% |
428,657
+42,523
| +11% | +$1.87M |
|
155
Ovintiv
OVV
$18.4B
| $16.5M | 0.1% |
+372,854
| New | +$19.2M |
|
|
156
Applied Materials
AMAT
$337B
| $16M | 0.09% |
175,525
-1,058,973
| -86% | -$116M |
|
157
PNC Financial Services
PNC
$97.3B
| $15.9M | 0.09% |
100,766
+12,309
| +14% | +$2.06M |
|
158
Littelfuse
LFUS
$10.1B
| $15M | 0.09% |
59,234
-7,220
| -11% | -$1.81M |
|
|
SBNY
159
DELISTED
Signature Bank
SBNY
| $14.9M | 0.09% |
83,221
-36,335
| -30% | -$8.14M |
|
|
PPLI
160
People Inc
PPLI
$2.89B
| $14.5M | 0.09% |
233,308
+51,993
| +29% | +$3.67M |
|
161
Surgery Partners
SGRY
$1.78B
| $14.3M | 0.08% |
495,695
| – | – |
|
162
Globant
GLOB
$1.73B
| $14.1M | 0.08% |
+81,253
| New | +$16.5M |
|
163
TE Connectivity
TEL
$58.5B
| $14.1M | 0.08% |
124,439
-249,713
| -67% | -$30.9M |
|
|
FISV
164
Fiserv Inc
FISV
$26.8B
| $14.1M | 0.08% |
157,938
+46,478
| +42% | +$4.51M |
|
165
Union Pacific
UNP
$169B
| $13.7M | 0.08% |
64,331
+23,309
| +57% | +$5.3M |
|
166
Cloudflare
NET
$117B
| $13.5M | 0.08% |
307,621
-279,385
| -48% | -$20.1M |
|
167
Intellia Therapeutics
NTLA
$1.63B
| $13.3M | 0.08% |
257,510
| – | – |
|
168
Norfolk Southern
NSC
$72B
| $13.3M | 0.08% |
58,417
+20,243
| +53% | +$4.97M |
|
|
CERE
169
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $13.2M | 0.08% |
500,000
-250,000
| -33% | -$7.1M |
|
170
Emerson Electric
EMR
$82.2B
| $13.2M | 0.08% |
165,812
-8,466
| -5% | -$746K |
|
171
Cannae Holdings
CNNE
$671M
| $13.1M | 0.08% |
675,275
+250,060
| +59% | +$5.24M |
|
172
Thermo Fisher Scientific
TMO
$232B
| $12.9M | 0.08% |
23,788
| – | – |
|
|
AXON
173
Axon Enterprise
AXON
$37.2B
| $12.8M | 0.08% |
137,310
-97,346
| -41% | -$10.3M |
|
174
Eli Lilly
LLY
$1.03T
| $12.6M | 0.07% |
38,994
-6,254
| -14% | -$1.88M |
|
175
Insmed
INSM
$27B
| $12.5M | 0.07% |
631,849
| – | – |
|
Similar funds
GAM
SAM
Polar Capital Holdings's Q2 2022 Portfolio in Review
As of Q2 2022, Polar Capital Holdings held 494 positions worth $17B, down 23% from $22.2B the previous quarter. Its ten largest holdings account for 43% of the portfolio.
Polar Capital Holdings withdrew a net $794M in Q2 2022, closing 61 positions and reducing 156 holdings. Its most notable exit was Biohaven Pharmaceutical Holding Company Ltd., an estimated $147M position sold in full.
By sector, the portfolio is most concentrated in Technology at 31% of assets, down from 33% a quarter earlier, followed by Industrials and Healthcare.
Against the trend, Polar Capital Holdings opened a new position in Sanofi worth $36.3M.
- Polar Capital Holdings's largest Q2 2022 buy was Sanofi: 725,000 shares worth $36.3M.
- Polar Capital Holdings added most to Salesforce in Q2 2022, an estimated $108M increase.
- Polar Capital Holdings's biggest Q2 2022 reduction was Applied Materials, cutting an estimated $116M.
- Polar Capital Holdings fully exited Biohaven Pharmaceutical Holding Company Ltd. in Q2 2022, selling an estimated $147M.
- Polar Capital Holdings's ten largest holdings make up 43% of its $17B portfolio in Q2 2022.
- Polar Capital Holdings opened 36 new positions and closed 61 in Q2 2022.
- Polar Capital Holdings's portfolio value fell 23% quarter-over-quarter to $17B.
Based on Polar Capital Holdings's 13F filing for Q2 2022, filed 15 Aug 2022.